Avastin and cetuximab extend the life of patients with KRAS wild-type bowel advanced cancer -
results Head-to-head trial presented at ASCO demonstrate significant value Avastin in treating advanced colon cancer regardless of KRAS biomarker
CALGB 80405, a major study III, independent phase to assess the superiority in overall survival (OS) of cetuximab Avastin ® (bevacizumab) when combined with either FOLFOX or FOLFIRI chemotherapy in people with previously untreated, advanced KRAS wild-type (metastatic) colorectal cancer failed to meet this primary endpoint. In contrast, the study found the two drugs help patients to nearly 30 months of extra life (median OS of 29.9 months for patients in the cetuximab treatment arms against 29.0 months for patients in the arm of Avastin therapy [HR=0.92, p=0.34]). The secondary endpoint of progression free survival (PFS) was also similar between treatments. Adverse events were as expected for both drugs. The CALGB 80405 data were presented at the 2014 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, at a plenary presentation abstracts reserved for "deemed to have the highest scientific merit and the greatest impact on research and cancer care. "
" the CALGB 80405 data address the question of which drug is the first treatment most appropriate line for patients with KRAS wild-type disease and strengthen the role Avastin as an effective and valuable treatment option for patients with advanced colorectal cancer regardless of KRAS status, "commented Dr. Sherif Raouf, consultant clinical oncologist at Barking, Havering and Redbridge university Hospitals NHS Trust." the study results also highlight the significant progress made in improving outcomes for people with bowel cancer and is important news for the 41,500 patients diagnosed with the disease each year in the UK. "
the results of CALGB 80405 reinforces that Avastin helps some patients with advanced bowel cancer are living longer than ever before. While there are more than 10 years, the median survival (median) for patients with newly diagnosed advanced cancer of the intestine was little more than a year (15 months), overall survival median for patients without mutations in the KRAS gene (KRAS wild type patients) treated with Avastin in this study was nearly two and a half years (29 months).
This study reinforces that Avastin plus chemotherapy remains an effective and valuable treatment option for the initial treatment for most patients regardless biomarker (KRAS) status.
EmoticonEmoticon